Clinical Trial for Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Have you been diagnosed with Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly NASH, and find yourself interested in learning more about new investigational developments for treating this severe form of Non-Alcoholic Fatty Liver Disease (NAFLD)? If yes, consider enrolling in Conquest Research’s latest MASH clinical trials, and become a part of the future of NAFLD treatment. Get in touch today to find out if you qualify as an eligible participant.
Eligibility Screening For Non-Alcoholic Steatohepatitis (NASH): What to Expect
At Conquest Research, we are dedicated to aiding those who have Nonalcoholic Fatty Liver Disease (NAFLD) or Metabolic Dysfunction-Associated Steatohepatitis (MASH) by providing access to clinical trials that may lead to viable treatments. To ensure the utmost safety of our participants, we require all potential candidates to undergo eligibility screening. Our screening process includes:
All of these steps are vital measures that give our participants the best chance of success when participating in our Metabolic Dysfunction-Associated Steatohepatitis (MASH) research.
Metabolic Dysfunction-Associated Steatohepatitis (MASH) is a severe type of Non-Alcoholic Fatty Liver Disease (NAFLD), characterized by an excessive accumulation of fat in the liver. This buildup can cause inflammation and damage to the liver cells, which can lead to scarring and cirrhosis. MASH is often referred to as a “silent disease” because it can develop without any noticeable symptoms. However, some people may experience fatigue, weakness, or abdominal pain. Risk factors for MASH and NAFLD include obesity, type 2 diabetes, high cholesterol, and high blood pressure. Treatment includes lifestyle changes around weight loss, exercise, and medication options to manage symptoms and prevent further liver damage.
Qualification Criteria For Metabolic Dysfunction-Associated Steatohepatitis (MASH) Clinical Trials
To qualify for Metabolic Dysfunction-Associated Steatohepatitis (MASH) clinical trials, patients should satisfy specific requirements, by going through a range of assessments. Assessments can range from physical examinations to consenting to diagnostic imaging, blood work, and liver biopsies, to disclosing their medical history along with any pre-existing conditions that could affect the study. Participants will also need to satisfy inclusion criteria like being of a certain age, and having a confirmed diagnosis of MASH and certain liver-related conditions.
Participants will also be required to complete comprehensive survey questionnaires, detailing the impact of the condition on their day-to-day life, such as changes in lifestyle, medication usage, and any other treatments they've attempted. Ultimately, this process helps guarantee the success of our MASH clinical trials and offers individuals impacted by this condition a potential chance for relief.
If you have any questions about the qualification process, contact your trial sponsor or find out if you qualify by clicking the button below.
Why Join a Metabolic Dysfunction-Associated Steatohepatitis (MASH) Clinical Trial Through Conquest Research?
Apart from paving the way for better health outcomes for those with MASH & NAFLD, there are certain benefits you can expect as a clinical trial participant.
Frequently Asked Questions About Metabolic Dysfunction-Associated Steatohepatitis (MASH) & Clinical Trials
Get Involved In Non-Alcoholic Steatohepatitis Clinical Trials
Join us in our Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Non-Alcoholic Fatty Liver Disease [NAFLD] clinical trials, as we find new treatments for this chronic liver disease that’s affecting millions of people worldwide. By joining in, you’ll have the opportunity to contribute to the development of new treatment options for MASH, which could improve the lives and health outcomes of those grappling with this debilitating disease. If you are someone you know is struggling with MASH, fill out the form today to see if you qualify for one of our open clinical trials.